Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc. is trading at $27.38, up 1.67% on the session. The 50 day average sits at $22.58 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 72.6, which reads as overbought, and MACD is bullish crossover. Volume is below average.

The nearest support is around $23.11 with resistance near $27.35, so that band frames the current range. Average daily movement is roughly $1.03, or about 3.8% of the share price, which is what any stop placement has to allow for. The overall health score of 74 out of 100 combines a trend score of 75, momentum of 78 and a risk score of 65.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.